Gunter Schneider
Overview
Explore the profile of Gunter Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
242
Citations
5856
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papargyriou A, Najajreh M, Cook D, Maurer C, Barthel S, Messal H, et al.
Nat Biomed Eng
. 2024 Dec;
PMID: 39658630
In patients with pancreatic ductal adenocarcinoma (PDAC), intratumoural and intertumoural heterogeneity increases chemoresistance and mortality rates. However, such morphological and phenotypic diversities are not typically captured by organoid models of...
2.
Tapia Contreras C, Falke J, Seifert D, Schneider C, Krauss L, Fang X, et al.
Mol Oncol
. 2024 Sep;
19(2):295-310.
PMID: 39253995
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, emphasizing the urgent need for effective therapies. The predominant driver in PDAC is mutated KRAS proto-oncogene, KRA, present in 90% of patients....
3.
Schneider C, Hilbert J, Genevaux F, Hofer S, Krauss L, Schicktanz F, et al.
Adv Sci (Weinh)
. 2024 Jun;
11(31):e2307695.
PMID: 38885414
Cancer cells must develop strategies to adapt to the dynamically changing stresses caused by intrinsic or extrinsic processes, or therapeutic agents. Metabolic adaptability is crucial to mitigate such challenges. Considering...
4.
Wirth M, Schneider G
Cancer Res
. 2024 Jun;
84(11):1739-1741.
PMID: 38831749
Epithelial-to-mesenchymal transition (EMT) is a classical cellular plasticity process induced by various cell-intrinsic and -extrinsic triggers. Although prominent factors, such as TGFβ, mediate EMT via well-characterized pathways, alternative avenues are...
5.
Wiessner J, Orben F, Schafer A, Fricke L, Schneider G, Reichert M, et al.
Endosc Int Open
. 2024 Mar;
12(3):E361-E366.
PMID: 38464982
The prognosis for pancreatic cancer remains poor. Molecular diagnostics and customized therapies are becoming increasingly important in clinical routine. Patient-derived, predictive model systems such as organoids have the potential to...
6.
Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauss L, Schneeweis C, et al.
Bioorg Chem
. 2024 Mar;
146:107248.
PMID: 38458892
No abstract available.
7.
Schneider C, Schneider G
EMBO Mol Med
. 2024 Feb;
16(3):429-431.
PMID: 38413839
No abstract available.
8.
Kern J, Schilling D, Schneeweis C, Schmid R, Schneider G, Combs S, et al.
Radiother Oncol
. 2023 Dec;
191:110059.
PMID: 38135186
Background And Purpose: Due to the high intrinsic radioresistance of pancreatic ductal adenocarcinoma (PDAC), radiotherapy (RT) is only beneficial in 30% of patients. Therefore, this study aimed to identify targets...
9.
Hasselluhn M, Schlosser D, Versemann L, Schmidt G, Ulisse M, Oschwald J, et al.
Gastroenterology
. 2023 Nov;
166(2):298-312.e14.
PMID: 37913894
Background & Aims: The highly heterogeneous cellular and molecular makeup of pancreatic ductal adenocarcinoma (PDAC) not only fosters exceptionally aggressive tumor biology, but contradicts the current concept of one-size-fits-all therapeutic...
10.
Krauss L, Schneider C, Hessmann E, Saur D, Schneider G
Cancer Metastasis Rev
. 2023 Sep;
42(4):1113-1131.
PMID: 37659057
Surgical resection, when combined with chemotherapy, has been shown to significantly improve the survival rate of patients with pancreatic ductal adenocarcinoma (PDAC). However, this treatment option is only feasible for...